Specific post-marketing surveillance of pazufloxacin (Pasil) Clinical efficacy and safety of pazufloxacin administered at a dose of 1,000 mg twice daily

Trial Profile

Specific post-marketing surveillance of pazufloxacin (Pasil) Clinical efficacy and safety of pazufloxacin administered at a dose of 1,000 mg twice daily

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Pazufloxacin (Primary)
  • Indications Pneumococcal infections; Respiratory tract infections; Sepsis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 13 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top